We could not find any results for:
Make sure your spelling is correct or try broadening your search.
Share Name | Share Symbol | Market | Type |
---|---|---|---|
Bellicum Pharmaceuticals Inc | NASDAQ:BLCM | NASDAQ | Common Stock |
Price Change | % Change | Share Price | Bid Price | Offer Price | High Price | Low Price | Open Price | Shares Traded | Last Trade | |
---|---|---|---|---|---|---|---|---|---|---|
0.00 | 0.00% | 0.25 | 0.20 | 0.50 | 0 | 01:00:00 |
Nine abstracts accepted, including two oral presentations
Among the highlights will be late interim analyses from the BP-004 trial in children with acute leukemias and nonmalignant blood diseases, as well as the comparator C-004 trial—a multicenter, observational study of similar pediatric patients receiving a matched unrelated donor (MUD) transplant. As part of these interim analyses, the presentations will include the first reports of transplant Event-Free Survival at 180 days, the primary endpoint of the studies that will serve as the basis for MAA filing in Europe. In addition, longer term follow-up of disease outcomes from several patient subsets, including ALL, AML, thalassemia major, and Fanconi anemia, will be presented. Finally, the cumulative clinical experience of patients in BP-004 who received rimiducid to treat steroid refractory Graft-versus-Host-Disease will also be presented. ASH 2018 is being held in San Diego, California on December 1-4.
RIVO-CEL PRESENTATION DETAILS
Poster Presentation: “Administration of BPX-501 Cells Following αβ T and B-Cell-Depleted HLA-Haploidentical HSCT (haplo-HSCT) in Children with Malignant or Non-Malignant Disorders”Abstract Number: 2171Session Name: 732. Clinical Allogeneic Transplantation: Results: Poster I Session Date: Saturday, December 1, 2018 Presentation Time: 6:15 p.m. – 8:15 p.m. PT
Oral Presentation: “Administration of BPX-501 Cells Following αβ T and B-Cell-Depleted HLA Haploidentical HSCT (haplo-HSCT) in Children with Acute Leukemias”Abstract Number: 307Session Name: 732. Clinical Allogeneic Transplantation: Results: Optimizing Outcomes After Allogeneic Transplantation Session Date: Sunday, December 2, 2018 Session Time: 7:30 a.m. - 9:00 a.m. PTPresentation Time: 7:30 a.m. PT
Oral Presentation: “Administration of BPX-501 Following αβ T and B-cell Depleted Haplo-HSCT in Children with Transfusion-Dependent Thalassemia”Abstract Number: 166Session Name: 112. Thalassemia and Globin Gene Regulation: ClinicalSession Date: Saturday, December 1, 2018Session Time: 2:00 p.m. - 3:30 p.m. PTPresentation Time: 2:45 p.m. PT
Poster Presentation: “Administration of Rimiducid Following Haploidentical BPX-501 Cells in Children with Malignant or Non-Malignant Disorders Who Develop Graft-versus-Host-Disease (GvHD)”Abstract Number: 2207Session Name: 801. Gene Therapy and Transfer: Poster I Session Date: Saturday, December 1, 2018Presentation Time: 6:15 p.m. - 8:15 p.m. PT
Poster Presentation: “Characterization of Allogeneic T Cells Expressing Inducible Caspase-9 Following Adoptive Transfer in Children Receiving an HLA-Haploidentical Hematopoietic Stem Cell Transplant for the Treatment of Myeloid Malignancies”Abstract Number: 4534Session Name: 703. Adoptive Immunotherapy: Poster III Session Date: Monday, December 3, 2018 Presentation Time: 6:00 p.m. - 8:00 p.m. PT
Poster Presentation: “Differential Expression of Inducible Caspase-9 (iC9) in Allogeneic T cells Allows Selective Depletion of Activated T Cells Following Exposure to Rimiducid and Permits In Vivo Allodepletion”Abstract Number: 3496 Session Name: 801. Gene Therapy and Transfer: Poster II Session Date: Sunday, December 2, 2018Presentation Time: 6:00 p.m. - 8:00 p.m. PT
Poster Presentation: “Administration of BPX-501 Cells Following αβ T and B-Cell-Depleted HLA-Haploidentical HSCT in Children with Fanconi Anemia”Abstract Number: 4654Session Name: 732. Clinical Allogeneic Transplantation: Results: Poster IIISession Date: Monday, December 3, 2018 Presentation Time: 6:00 p.m. - 8:00 p.m. PT
Poster Presentation: “A Simplified Method for Transduction and Expansion of T Cells for Clinical Application”Abstract Number: 4555 Session Name: 711. Cell Collection and Processing: Poster III Session Date: Monday, December 3, 2018 Presentation Time: 6:00 p.m. - 8:00 p.m. PT
CONTROLLABLE CAR PRESENTATION DETAILS
Poster Presentation: “Regulated Natural Killer Cell Expansion and Anti-Tumor Activity with Inducible MyD88/CD40”Abstract Number: 4550Session Name: 703. Adoptive Immunotherapy: Poster III Session Date: Monday, December 3, 2018 Presentation Time: 6:00 p.m. - 8:00 p.m. PT
About Bellicum Pharmaceuticals Bellicum is a clinical stage biopharmaceutical company striving to deliver cures through controllable cell therapies. The Company’s next-generation product candidates are differentiated by powerful cell signaling technologies designed to produce more effective CAR-T, TCR and allogeneic T cell therapies. Its lead product candidate, rivo-cel, is an allogeneic polyclonal T cell product that has shown promising results in reducing leukemia relapse after a stem cell transplant. Bellicum’s lead GoCAR-T candidate, BPX-601, is designed to be a more efficacious CAR-T cell product capable of overriding key immune inhibitory mechanisms. More information can be found at www.bellicum.com.
Source: Bellicum Pharmaceuticals
Investors: Solebury Trout Chad Rubin 646-378-2947 crubin@soleburytrout.com Media: Solebury Trout Brad Miles 646-513-3125 bmiles@soleburytrout.com
1 Year Bellicum Pharmaceuticals Chart |
1 Month Bellicum Pharmaceuticals Chart |
It looks like you are not logged in. Click the button below to log in and keep track of your recent history.
Support: +44 (0) 203 8794 460 | support@advfn.com
By accessing the services available at ADVFN you are agreeing to be bound by ADVFN's Terms & Conditions